Business Wire

I-CARE

15.2.2024 14:31:33 CET | Business Wire | Press release

Share
I-care Launches the Wi-care 130 G23, a 100% Belgian High-precision Vibration Sensor With 3 Times More Powerful Data Flow

I-care, world leader in machine health, today presented the latest innovation in its Wi-care product range, the Wi-care 130 G23. This is the very first high-precision vibration sensor manufactured entirely in Belgium, capable of predicting more and more industrial breakdowns at an ever earlier stage. It is 100% autonomous, and therefore wireless, with a data flow that is 3 times more powerful and a battery life of 5 years. Thanks to this new technological innovation, I-care is strengthening AI-powered industrial maintenance 4.0. and enabling industries around the world to be more productive, safer and more sustainable.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215735570/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Wi-care 130 G23 (Photo: I-care)

The Wi-care 130 G23, the very first sensor to be manufactured entirely in Belgium, is a revolution in the predictive maintenance business. It is an innovative tool capable of carrying out 3 types of measurement on machines simultaneously: vibration analysis, shock identification and temperature monitoring. It incorporates the state-of-the-art technologies, in particular piezoelectric sensors, and works on all types of industrial machine.

The Wi-care 130 G23 is 100% autonomous, and therefore wireless. It has a battery that will last for more than 5 years of uninterrupted use, even when taking high-precision measurements that consume a lot of energy. The sensor is ATEX certified, with a data stream 3 times more powerful, offering high resolution and high frequency.

Like all products in the Wi-care range, this new sensor from I-care is fully integrated into the WaaS (Wi-care as a Service) ecosystem, an all-inclusive machine maintenance solution covering everything from hardware to support services via the iSee platform, including analysis and reporting. .

I-care is an expert in analysing machine vibrations to predict industrial failures months or even years before they occur. The Wi-care 130 G23 enables errors to be detected at an early stage, so that more and more industrial failures can be predicted earlier and earlier. In this way, I-care is delivering on its mission to "change the way the world works" by making industries around the world more efficient, safer and more environmentally friendly.

"With the Wi-care 130 G23, not only the design but also, and above all, the performance of Wi-care has been enormously improved. It's a real revolution, and 100% Belgian," says Fabrice Brion, CEO of I-care. "Above all, it's about enabling the industrial manufacturing companies to work better. At I-care, this is our way of contributing to a more efficient and sustainable economy.”

About I-care
The I-care Group is a world leader in machine health. Our mission is to change the way the world works. Our AI and data-driven solutions predict industrial failures months or even years before they occur. Thanks to I-care, machines around the world are safer, more productive and more sustainable. Founded in 2004 in Mons, Belgium, we employ over 800 people, with 36 offices in 16 countries (Asia-Pacific, EMEA and the US) and customers in over 55 countries.

Pictures Wi-care 130 G23

Please find the pictures of the Wi-care 130 G23 here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240215735570/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release

A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye